HEALTH● LOWAug 14 · Aug 14, 2026, 12:31 PM
Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’s
Seeking Alpha Tech
Lantheus has received approval from the FDA for its tau PET imaging agent, intended for use in Alzheimer's disease. This approval marks a significant development in medical diagnostics for Alzheimer's.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH41m agoPope doing physical therapy, good recovery of lung that was operated onANSA [en]HEALTH41m agoPope doing physical therapy, good recovery of the operated lungANSA [en]HEALTH1h agoWHO boosts preparedness for Ebola-related virus in 3 countriesVanguard NigeriaHEALTH2h agoNAFDAC records 213 raids, 474 new cases in eight monthsPremium Times